The overall objective of the proposed research on the modification of peroxisome proliferator-induced hepatocarcinogenesis is to enhance our present understanding of the mechanism(s) of carcinogenesis by di-(2-ethylhexyl) phthalate (DEHP), a widely used industrial phthalate ester plasticizer, and certain hypolipidemic agents such as ciprofibrate, which constitute two very important classes of peroxisome proliferators. Peroxisome proliferators exert unique biological and biochemical alterations in liver. These include profound proliferation of the cytoplasmic organelle peroxisome and increase in H202 generating peroxisomal long-chain fatty acid Beta-oxidation enzyme system. Since these chemicals are non-mutagenic, non-DNA damaging, and do not form adducts with DNA, it is suggested that their carcinogenicity is due to sustained proliferation of peroxisomes leading to excess generation of H202 and other active oxygen species. The proposed studies of modification of peroxisome proliferator carcinogenesis with antioxidants (vitamin E, and ethoxyquin) and with high-dietary fat should generate new information regarding the role of lipid peroxidation and antioxidants in liver carcinogenesis. This proposal includes studies on: 1) the effect of antioxidant ethoxyquin on carcinogenesis by DEHP; 2) the role of dietary vitamin E on inhibiting peroxisome proliferator carcinogenesis; 3) the role of dietary fat on enhancing peroxisome proliferator carcinogenesis; 4) the effect of ethoxyquin on cell proliferation and growth of putative preneoplastic lesions in liver induced by a peroxisome proliferator; and 5) the effect of ethoxyquin on DNA repair and alterations in protein synthesis and certain enzymes in liver induced by a peroxisome proliferator. It is anticipated that antioxidants may prove useful for individuals who are exposed to phthalate ester plasticizers and those requiring continued use of anti-hyperlipidemic drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA032504-06
Application #
3170398
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1982-05-01
Project End
1989-02-28
Budget Start
1988-03-01
Budget End
1989-02-28
Support Year
6
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
School of Medicine & Dentistry
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Yeldandi, A V; Subbarao, V; Rajan, A et al. (1989) gamma-Glutamyltranspeptidase-negative phenotypic property of preneoplastic and neoplastic liver lesions induced by ciprofibrate does not change following 2-acetylaminofluorene administration. Carcinogenesis 10:797-9
Waddell, W J; Marlowe, C; Rao, M S et al. (1989) In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse. Carcinogenesis 10:221-3
Rao, M S; Usuda, N; Subbarao, V et al. (1987) Absence of gamma-glutamyl transpeptidase activity in neoplastic lesions induced in the liver of male F-344 rats by di-(2-ethylhexyl)phthalate, a peroxisome proliferator. Carcinogenesis 8:1347-50
Reddy, J K; Reddy, M K; Usman, M I et al. (1986) Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug. Environ Health Perspect 65:317-27
Goel, S K; Lalwani, N D; Reddy, J K (1986) Peroxisome proliferation and lipid peroxidation in rat liver. Cancer Res 46:1324-30
Gupta, R C; Goel, S K; Earley, K et al. (1985) 32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro. Carcinogenesis 6:933-6
Watanabe, T; Lalwani, N D; Reddy, J K (1985) Specific changes in the protein composition of rat liver in response to the peroxisome proliferators ciprofibrate, Wy-14,643 and di-(2-ethylhexyl)phthalate. Biochem J 227:767-75